Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

2016371 citationsJournal Articlebronze Open Access

Authors

Dhruv S. Kazi · University of California, San Francisco

Andrew E. Moran · Columbia University

Pamela G. Coxson · University of California, San Francisco

Joanne Penko · University of California, San Francisco

Daniel A. Ollendorf · Institute for Clinical and Economic Review

Steven D. Pearson · Institute for Clinical and Economic Review

Jeffrey A. Tice

Abstract

Assuming 2015 prices, PCSK9 inhibitor use in patients with heterozygous FH or ASCVD did not meet generally acceptable incremental cost-effectiveness thresholds and was estimated to increase US health care costs substantially. Reducing annual drug prices from more than $14,000 to $4536 would be necessary to meet a $100,000 per QALY threshold.

Topics & Keywords

Lipoproteins and Cardiovascular Health Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 316, Issue 7, pp. 743-743

DOI: 10.1001/jama.2016.11004

Field-Weighted Citation Impact: 59.69